In Devices, the Exit Door Stays Ajar--Barely
Executive SummaryOver the past several years as the public market has all but turned its back on small-cap medical devices, the industry's saving grace has been the acquisition appetite of large medical device firms who were willing to pay reasonable and sometimes even spectacular prices for samll companies with promising technology. But over the past year or so, even this exit vehicle for small cap companies seems to be disappearing.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.